{"id":917,"date":"2021-03-03T00:12:22","date_gmt":"2021-03-03T00:12:22","guid":{"rendered":"https:\/\/mitogendx.com\/faq\/est-il-utile-de-repeter-et-de-surveiller-les-niveaux-dautoantibody-dans-le-suivi-des-patients-presentant-la-maladie-rhumatismale-systemique\/"},"modified":"2021-03-03T00:12:26","modified_gmt":"2021-03-03T00:12:26","slug":"est-il-utile-de-repeter-et-de-surveiller-les-niveaux-dautoantibody-dans-le-suivi-des-patients-presentant-la-maladie-rhumatismale-systemique","status":"publish","type":"faq","link":"https:\/\/mitogen.dev5.oracastdev.com\/fr\/faq\/est-il-utile-de-repeter-et-de-surveiller-les-niveaux-dautoantibody-dans-le-suivi-des-patients-presentant-la-maladie-rhumatismale-systemique\/","title":{"rendered":"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ?"},"content":{"rendered":"<p><em>En g\u00e9n\u00e9ral, le titer de d\u00e9pistage HEp-2 IFA n\u2019est pas corr\u00e9l\u00e9 avec des caract\u00e9ristiques cliniques telles que l\u2019activit\u00e9 de la maladie ou les pouss\u00e9es, et n\u2019est donc pas un param\u00e8tre particuli\u00e8rement utile pour suivre le cours de la maladie ou estimer l\u2019efficacit\u00e9 du traitement (10;11).  <\/em><strong><em>Il convient de souligner que cette conclusion n\u2019est pas fond\u00e9e sur des \u00e9tudes de laboratoire prospectives minutieuses utilisant des tests normalis\u00e9s sur des plates-formes diagnostiques avanc\u00e9es ou dans des indices d\u00e9finis de maladie clinique (p. ex. SLEDAI, SLAM).  <\/em><\/strong><em>En g\u00e9n\u00e9ral, les titres de l\u2019IFA Hep-2 peuvent fluctuer au fil du temps, et les anticorps ont tendance \u00e0 \u00eatre d\u00e9tectables en phases d\u2019activit\u00e9 de la maladie et de r\u00e9mission (12;13), bien qu\u2019il y ait des exceptions signal\u00e9es. Une exception peut \u00eatre la pr\u00e9sence de niveaux \u00e9lev\u00e9s d\u2019anticorps anti-U1-RNP qui sont caract\u00e9ristiques de la maladie mixte des tissus conjonctifs (14).  <\/em><\/p>\n<p><em>Une autre exception est li\u00e9e \u00e0 la preuve que les niveaux d\u2019anticorps anti-DsDNA sont souvent corr\u00e9l\u00e9s avec certaines caract\u00e9ristiques cliniques, par exemple la n\u00e9phrite du lupus, et sa d\u00e9termination est obligatoire dans le travail diagnostique des patients atteints de SLE et le suivi des cas nephritiques (15;16). Cependant, il est appr\u00e9ci\u00e9 que certains essais pour la d\u00e9tection anti-DsDNA sont meilleurs que d\u2019autres dans la mesure des changements cliniquement importants dans les niveaux d\u2019anticorps.  <\/em><\/p>\n","protected":false},"template":"","class_list":["post-917","faq","type-faq","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ? - MitogenDx<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ? - MitogenDx\" \/>\n<meta property=\"og:description\" content=\"En g\u00e9n\u00e9ral, le titer de d\u00e9pistage HEp-2 IFA n\u2019est pas corr\u00e9l\u00e9 avec des caract\u00e9ristiques cliniques telles que l\u2019activit\u00e9 de la maladie ou les pouss\u00e9es, et n\u2019est donc pas un param\u00e8tre particuli\u00e8rement utile pour suivre le cours de la maladie ou estimer l\u2019efficacit\u00e9 du traitement (10;11). Il convient de souligner que cette conclusion n\u2019est pas fond\u00e9e [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"MitogenDx\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-03T00:12:26+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/\",\"url\":\"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/\",\"name\":\"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ? - MitogenDx\",\"isPartOf\":{\"@id\":\"https:\/\/mitogendx.com\/fr\/#website\"},\"datePublished\":\"2021-03-03T00:12:22+00:00\",\"dateModified\":\"2021-03-03T00:12:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/mitogendx.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mitogendx.com\/fr\/#website\",\"url\":\"https:\/\/mitogendx.com\/fr\/\",\"name\":\"MitogenDx\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/mitogendx.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mitogendx.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mitogendx.com\/fr\/#organization\",\"name\":\"MitogenDx\",\"url\":\"https:\/\/mitogendx.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/mitogendx.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mitogen.dev5.oracastdev.com\/wp-content\/uploads\/2020\/07\/logo.webp\",\"contentUrl\":\"https:\/\/mitogen.dev5.oracastdev.com\/wp-content\/uploads\/2020\/07\/logo.webp\",\"width\":80,\"height\":68,\"caption\":\"MitogenDx\"},\"image\":{\"@id\":\"https:\/\/mitogendx.com\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ? - MitogenDx","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ? - MitogenDx","og_description":"En g\u00e9n\u00e9ral, le titer de d\u00e9pistage HEp-2 IFA n\u2019est pas corr\u00e9l\u00e9 avec des caract\u00e9ristiques cliniques telles que l\u2019activit\u00e9 de la maladie ou les pouss\u00e9es, et n\u2019est donc pas un param\u00e8tre particuli\u00e8rement utile pour suivre le cours de la maladie ou estimer l\u2019efficacit\u00e9 du traitement (10;11). Il convient de souligner que cette conclusion n\u2019est pas fond\u00e9e [&hellip;]","og_url":"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/","og_site_name":"MitogenDx","article_modified_time":"2021-03-03T00:12:26+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/","url":"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/","name":"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ? - MitogenDx","isPartOf":{"@id":"https:\/\/mitogendx.com\/fr\/#website"},"datePublished":"2021-03-03T00:12:22+00:00","dateModified":"2021-03-03T00:12:26+00:00","breadcrumb":{"@id":"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mitogendx.com\/faq\/is-it-useful-to-repeat-and-monitor-autoantibody-levels-in-the-follow-up-of-patients-with-systemic-rheumatic-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mitogendx.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Est-il utile de r\u00e9p\u00e9ter et de surveiller les niveaux d\u2019autoantibody dans le suivi des patients pr\u00e9sentant la maladie rhumatismale syst\u00e9mique ?"}]},{"@type":"WebSite","@id":"https:\/\/mitogendx.com\/fr\/#website","url":"https:\/\/mitogendx.com\/fr\/","name":"MitogenDx","description":"","publisher":{"@id":"https:\/\/mitogendx.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mitogendx.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/mitogendx.com\/fr\/#organization","name":"MitogenDx","url":"https:\/\/mitogendx.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/mitogendx.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/mitogen.dev5.oracastdev.com\/wp-content\/uploads\/2020\/07\/logo.webp","contentUrl":"https:\/\/mitogen.dev5.oracastdev.com\/wp-content\/uploads\/2020\/07\/logo.webp","width":80,"height":68,"caption":"MitogenDx"},"image":{"@id":"https:\/\/mitogendx.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/mitogen.dev5.oracastdev.com\/fr\/wp-json\/wp\/v2\/faq\/917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mitogen.dev5.oracastdev.com\/fr\/wp-json\/wp\/v2\/faq"}],"about":[{"href":"https:\/\/mitogen.dev5.oracastdev.com\/fr\/wp-json\/wp\/v2\/types\/faq"}],"wp:attachment":[{"href":"https:\/\/mitogen.dev5.oracastdev.com\/fr\/wp-json\/wp\/v2\/media?parent=917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}